Meiogen is a Delaware corporation closely held by a group of private investors that includes physician and basic scientists.  We are focused on commercializing our lead compound Normferon™, a well-characterized interferon inhibitor, to meet an unmet need in neurological conditions associated with pathologically excessive interferon levels.  Together, these conditions affect millions of people worldwide.

The Founder and CSO of Meiogen is Dr. Leonard E. Maroun, former Professor of Medical Microbiology and Immunology at Southern Illinois University School of Medicine, Springfield, Illinois. Dr. Maroun graduated from Notre Dame and worked as a research technician for two years before returning to graduate school at the Catholic University of America where he earned his Ph.D. in Cell Biology. He went on to post-doctoral training at the NIH, National Institute of Neurological Diseases and Stroke, and later joined the faculty at Southern Illinois University School of Medicine. He is the author of numerous scientific publications and the recipient of diverse research awards in cancer, heart disease, Down syndrome and Alzheimer's Disease. Dr. Maroun was Professor and Chair of the Department of Microbiology & Immunology at the Saint Matthews University School of Medicine in Grand Cayman, Cayman Islands. By invitation, he later joined the Linda Crnic Institute for Down Syndrome at the University of Colorado School of Medicine.